NON-INVASIVE PROGNOSTICATION AND MINIMAL RESIDUAL DISEASE MONITORING OF MYD88 (SIE 2026) - Oct 6, 2026 - Abstract #C024; Pres time: Sep 21, 2026; 03:40 PM - 05:10 PM; Location: HALL 1; P | "Bendamustine-rituximab yielded higher MRD negativity (43%, 12/28) compared to DRC (9%, 2/23). Conclusions. These results provide prospective evidence for MYD88 L265P assessment by ddPCR as a non-invasive tool for diagnosis, outcome prediction and MRD monitoring in IgM gammopathies, supporting its integration into clinical practice and future trial design."
IO biomarker • Minimal residual disease • Non-invasive • Residual disease • Tumor mutational burden • Hematological Malignancies • Monoclonal Gammopathy • MYD88 • TMB
|
|
E. Amaducci1; D. Drandi1; S. Zibellini2; L. Marcheselli3; C. Varraso2; E. Genuardi1; I. Dogliotti4; E. Cappello2; F. Cavallo1,4; C. Sasso1; A. Ferrari5; B. Bianchi6; M. Deodato7; L. Laurenti8; P. Tosi9; E. Cencini10; G. Loseto11; D. Marino12; M. Marchetti13,14; F. Russo15; A. Sica16; J. Olivieri17; G. Favrin2; C. Jiménez Sánchez18; N. Puig18; L. Arcaini2; B. Bruno1,4; R. García-Sanz19; S. Ferrero1,4; M. Varettoni2
|